Williams v Quest/Athena | GenomeWeb

Williams v Quest/Athena

Experts pointed out the lack of clarity in professional standards and regulations when it comes to dealing with genetic variation in patient care. 

A high-profile, independent committee is considering the liability issues impacting labs as genetic testing increasingly becomes integrated into patient care.

It is now up to Margaret Seymour, a senior judge in US District Court in the District of South Carolina, whether Williams' case should be dismissed or decided by a jury.

The affidavit from pediatric neurologist Max Wiznitzer is part of a plan by Amy Williams' lawyers to convince the court to take up their client's case.

In response to the plaintiff's amended complaint, Quest and Athena have filed a new motion to dismiss making similar arguments focused on statute of limitations and repose.

Williams is within the time frame in which she can sue, her lawyers maintain, since she didn't know about the lab's "mistake" until last year.

The companies want the court to dismiss Williams' case because the statute of limitations has expired and the "plaintiff does not have a viable claim for relief."

The companies filed a notice to move the case to the South Carolina District Court and said in response to interrogatories that the deceased child's doctors may be liable.

The tragic case exposes critical gaps in how testing firms currently interpret, classify, and report variants, according to genomics experts.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.